Polyphor announces successful end of phase II meeting with FDA for Murepavadin in nosocomial pneumonia(PresseBox) (Allschwil, Switzerland, )
The trial design, discussed in several interactions with the FDA, includes a 28-day mortality endpoint and a non-inferiority margin which corresponds to an overall trial size of less than 300 patients. It also includes several measures aimed at ensuring the feasibility of the study.
Polyphor has thereby also achieved the requirements to release the next tranche of financing.
Giacomo Di Nepi, CEO of Polyphor, said: "We are pleased with the productive interactions and the valuable direction we received from the FDA, and we appreciate the always constructive dialogue had with the FDA over the last months to define the best way to develop a mono-pathogen antibiotic for Pseudomonas aeruginosa and bring it to patients affected by nosocomial pneumonia - a disease with an unacceptable mortality rate of 30-40%".
The Company is working in collaboration with its investigators to finalize the detailed protocol design and taking all the steps for the operational preparation, centers' selection and trial launch, with the objective of starting the overall phase III program in the second half of 2017 and recruiting the first patient by Q1/2018.
About Nosocomial Pneumonia from Pseudomonas Aeruginosa
Pseudomonas aeruginosa (PA) is a major hospital-associated pathogen that can cause severe infections, most notably in hospitalized patients, especially those on ventilators. Ventilator-associated pneumonia (VAP) contributes to approximately half of all cases of hospital-acquired pneumonia and is the second most common nosocomial infection in the intensive care unit and the most common in the mechanically ventilated patients. Compared with other pathogens, PA is very difficult to eradicate as it displays high intrinsic resistance to a wide variety of antibiotics, including aminoglycosides, fluoroquinolones and ß-lactams. Carbapenem-resistant PA is considered one of the top three most dangerous pathogens by the World Health Organization. An estimated 200,000-250,000 patients in Europe and the US are diagnosed each year with nosocomial pneumonia from PA., of which up to over 50% are diagnosed with resistant pathogens, resulting in a mortality rate of 30-40%.
Murepavadin (POL7080) is the first representative of the Outer Membrane Protein Targeting Antibiotics (OMPTA) class, a class of antibiotics against Gram-negative bacteria with a novel mode of action discovered by Polyphor. Given its specific mechanism of action, Murepavadin is highly potent and unlikely to generate resistance or negatively impact the patient's native bacterial flora. No cross-resistance with current standard of care antibiotics have been observed with Murepavadin. It is the first new class of antibiotics against Gram-negative pathogens to enter late-stage clinical development in over 40 years. Murepavadin is being developed for the treatment of nosocomial pneumonia (VAP and HAP) caused by infections through Pseudomonas aeruginosa, including its resistant strains.